BIND Therapeutics maintained as an Outperform, says Credit Suisse Amgen (AMGN) declined to exercise its option on BIND Therapeutics' Accurin technology following completion of the collaboration. Credit Suisse does not view this as a negative read through for BIND-014 and continues to believe the technology is a valuable platform and expects Ph II results for BIND-014 in 2H 2014 to be a catalyst. The firm maintains its Outperform rating but lowers its price target to $20 from $21.
News For BIND;AMGN From The Last 14 Days
Check below for free stories on BIND;AMGN the last two weeks.